hrp0094s2.1 | Recent Breakthroughs in our Understanding of Calcium and Phosphate Homeostasis | ESPE2021

Circadian rhythms of skeletal homeostasis.

Kawai Masanobu ,

Circadian clock system is an evolutionarily conserved system, by which organisms adapt their metabolic activities to environmental inputs including nutrient availability. The master pacemaker of the clock system is located in the suprachiasmatic nucleus (SCN) in the hypothalamus. The neurons in the SCN are entrained by the signals from the light through the retinal-hypothalamic tract and the light-dark cycle of the environment creates the rhythmic patterning of behavioral and ...

hrp0092p2-170 | GH and IGFs | ESPE2019

Growth Hormone Therapy in Patients with SGA Short Stature Improves Body Composition by Increasing Muscle Mass and Bone Mineral Density Rather Than Decreasing Fat Mass

Maeyama Takatoshi , Ida Shinobu , Shoji Yasuko , Etani Yuri , Kawai Masanobu

Background: Children born SGA have been implicated to be at higher risk for subsequent obesity; however, the body composition, especially fat distribution, in SGS short stature (SGA-SS) patients and the effects of growth hormone (GH) therapy on body composition in SGA-SS have not been fully studied.Purpose: To unravel the effects of GH therapy on body fat mass, body fat distribution, muscle mass, and bone mineral density...

hrp0092p1-416 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology (2) | ESPE2019

Creating a Clinical Evaluation System for Simple and Comprehensive Scoring of Differences/Disorders of Sexual Development

Nagamatsu Fusa , Kawai Masanobu , Sato Hiroyuki , Shoji Yasuko , Matsumoto Fumi , Ida Shinobu , Hasegawa Yukihiro

Background: The Prader and Quigley classifications (P/Q-C), used widely to evaluate external/internal genitalia in differences/disorders of sexual development (DSD) patients, are sometimes unsuitable for determining the stage/grade because they were originally designed to assess 46,XX 21-hydroxylase deficiency (21OHD) and 46,XY androgen receptor defects (ARD), respectively. The external masculinization score (EMS) is also used to assess masculinization of the ...

hrp0092p2-252 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

Clinical Evaluation of Newly Developed Scoring System for DSD (DSD-SS): Association of DSD-SS With Assigned Gender in 45,X/46,XY Mosaicism

Kawai Masanobu , Nagamatsu Fusa , Shoji Yasuko , Matsumoto Fumi , Sato Hiroyuki , Hasegawa Yukihiro , Ida Shinobu

Background: We have proposed a simple and comprehensive scoring system to evaluate clinical features of differences/disorders of sexual development (DSD); however, its clinical evaluation has not been performed.Aim: To evaluate the association between this newly proposed DSD scoring system (DSD-SS) and assigned gender in patients with 45,X/46,XY mosaicism.Methods: DSD-SS involves e...

hrp0097p1-289 | GH and IGFs | ESPE2023

Long-term effectiveness and safety of growth hormone therapy in Japanese children with short stature due to Noonan syndrome (NS): real-world data

Muroya Koji , Kawai Masanobu , Yamagishi Hiroyuki , Endo Takaaki , Pietropoli Alberto , Horikawa Reiko

Norditropin® was approved for children with short stature due to NS in Japan in 2017. The aim of this post-marketing surveillance study was to evaluate long-term safety and effectiveness of Norditropin® for the approved indication. This real-world non-interventional study (NCT03435627) was conducted February 2018–January 2022. Seventy patients enrolled: 35 received Norditropin® after study initiation (new patients); 35 were previously ra...

hrp0095p1-305 | Growth and Syndromes | ESPE2022

Once-Weekly Somapacitan vs Daily Growth Hormone in Children Born Small for Gestational Age: 1-year Results from a Randomised Phase 2 Trial

Juul Anders , Backeljauw Philippe , Bakhtadze Bagci Ekaterine , Højby Michael , Kawai Masanobu , Juul Kildemoes Rasmus , Linglart Agnès , Zuckerman-Levin Nehama , Horikawa Reiko

Treatment of short stature in children born small for gestational age (SGA) requires daily growth hormone (GH) injections that can be burdensome for patients and caregivers. Once-weekly somapacitan is a long-acting GH in phase 3 development for replacement therapy in children with GH deficiency. We report the 52-week results of the first phase 2, multinational, randomised, open-label, controlled, dose-finding trial (NCT03878446) investigating efficacy and safety of somapacitan...

hrp0092p1-243 | Multisystem Endocrine Disorders | ESPE2019

A Nation-Wide Questionnaire Survey Targeting Japanese Pediatric Endocrinologists Regarding Transitional Care in Pediatric and Adolescent Cancer Patients

Miyoshi Yoko , Yorifuji Tohru , Yokoya Susumu , Nagasaki Keisuke , Kawai Masanobu , Ishiguro Hiroyuki , Okada Satoshi , Kanno Junko , Takubo Noriyuki , Muroya Koji , Ito Junko , Horikawa Reiko , Shimizu Chikako , Ozono Keiichi

Background: While existing guidelines recommend long-term follow-up of childhood cancer survivors (CCS), transitional care among pediatric and adult endocrinologists has not been established in Japan.Objective and Hypotheses: To know the present situation and to cultivate a better understanding, we had conducted a nation-wide survey targeting Japanese pediatric endocrinologists.Method</stro...